Citations

Clear

414 citation(s) found for "Collins, S".

Enhancing diversity, equity, inclusion, and accessibility in eosinophilic gastrointestinal disease research: the consortium for eosinophilic gastrointestinal disease researchers’ journey
Chehade, Mirna , Furuta, Glenn T. , Abonia, J. Pablo , Aceves, Seema S. , Bose, Paroma , Dellon, Evan S. , Eickel, Grant, Gupta, Sandeep K. , Hiremath, Girish , Howard, Amari, Kesh, Susamita, Khoury, Paneez , Kocher, Kendra, Kodroff, Ellyn, Kyle, Shay, Mak, NaDea , McCoy, D. E., Mehta, Pooja , Menard‐Katcher, Paul , Paliana, Ally, Sable, Kathleen, Schmitt, Cara, Scott, Melissa, Strobel, Mary Jo, Zicarelli, Amy, Muir, Amanda B. , Wright, Benjamin L. , Bailey, Dominique D., Wright, Benjamin L , Klion, Amy D. , Collins, Margaret H. , Davis, Carla McGuire , Falk, Gary W. , Jensen, Elizabeth T. , McCoy, Dawn, Mukkada, Vincent A. , Rothenberg, Marc E. , Spergel, Jonathan M. , Wechsler, Joshua B , Yang, Guang‐Yu

Mayo Clinic

Therapeutic Advances in Rare Disease | August 14, 2023 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/26330040231180895 | PMID 37588777 Get It

In response to the social inequities that exist in health care, the NIH-funded Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) recently formed a diversity committee to examine systemic racism and implicit bias in the care and research of eosinophilic gastrointestinal diseases (EGIDs). Herein, we describe our process, highlighting milestones and issues addressed since the committee’s inception, which we hope will inspire other researchers to enhance diversity, equity, inclusion, and accessibility (DEIA) in their fields. Our journey began by establishing mission and vision statements to define the purpose of the committee. Regular discussion of diversity-related topics was incorporated into existing meetings and web-based materials were shared. This was followed by educational initiatives, including establishing a library of relevant publications and a speaker series to address DEIA topics. We then established a research agenda focused on the following actionable items: (1) to define what is known about the demographics of EGIDs by systematic review of population-based studies; (2) to develop a practical tool for reporting participant demographics to reduce bias in EGID literature; (3) to examine health disparities in the care of individuals with eosinophilic esophagitis who present to the emergency department with an esophageal food impaction; (4) to examine how access to a gastroenterologist affects the conclusions of published research examining the prevalence of pediatric eosinophilic esophagitis; and (5) to develop a model for examining the dimensions of diversity, and provide a framework for CEGIR’s ongoing projects and data capture. In addition to promoting consciousness of DEIA, this initiative has fostered inclusivity among CEGIR members and will continue to inspire positive changes in EGID care and research.
Preclinical tendon and ligament models: Beyond the 3Rs (replacement, reduction, and refinement) to 5W1H (why, who, what, where, when, how)
Little, Dianne , Amadio, Peter C. , Awad, Hani A. , Cone, Stephanie G. , Fisher, Matthew B. , Huang, Alice H. , Koch, Drew W. , Madi, Rashad , McGilvray, Kirk C. , Schnabel, Lauren V. , Thomopoulos, Stavros , Zhao, Chunfeng , Dyment, Nathaniel A , Fisher, Matthew B , Huang, Alice H , McGilvray, Kirk , Schnabel, Lauren V , Shetye, Snehal S , Thomopoulos, Stavros , Zhao, Chunfeng , Soslowsky, Louis J , Awad, Hani A , Dyment, Nathaniel A. , Kuntz, Andrew F.

Mayo Clinic

Journal of Orthopaedic Research | August 13, 2023 | Volume: 41 | Issue: 10 | Pages: 2133-2162

10.1002/jor.25678 | PMID 37573480 Get It

AbstractSeveral tendon and ligament animal models were presented at the 2022 Orthopaedic Research Society Tendon Section Conference held at the University of Pennsylvania, May 5 to 7, 2022. A key objective of the breakout sessions at this meeting was to develop guidelines for the field, including for preclinical tendon and ligament animal models. This review summarizes the perspectives of experts for eight surgical small and large animal models of rotator cuff tear, flexor tendon transection, anterior cruciate ligament tear, and Achilles tendon injury using the framework: “Why, Who, What, Where, When, and How” (5W1H). A notable conclusion is that the perfect tendon model does not exist; there is no single gold standard animal model that represents the totality of tendon and ligament disease. Each model has advantages and disadvantages and should be carefully considered in light of the specific research question. There are also circumstances when an animal model is not the best approach. The wide variety of tendon and ligament pathologies necessitates choices between small and large animal models, different anatomic sites, and a range of factors associated with each model during the planning phase. Attendees agreed on some guiding principles including: providing clear justification for the model selected, providing animal model details at publication, encouraging sharing of protocols and expertise, improving training of research personnel, and considering greater collaboration with veterinarians. A clear path for translating from animal models to clinical practice was also considered as a critical next step for accelerating progress in the tendon and ligament field.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Ansell, Stephen M. , Bröckelmann, Paul J. , Keudell, Gottfried von , Lee, Hun Ju , Santoro, Armando , Zinzani, Pier Luigi , Cohen, Jonathon B. , Willenbacher, Wolfgang , Wen, Rachael, Akyol, Alev, Mikita-Geoffroy, Joanna, Engert, Andreas , Armand, Philippe , Cohen, Jonathon B , Savage, Kerry J , Jäger, Ulrich , Willenbacher, Wolfgang , Shipp, Margaret Ann , Zinzani, Pier Luigi , Santoro, Armando , Collins, Graham P. , Boer, Jan Paul de , Kuruvilla, John , Savage, Kerry J. , Trněný, Marek

Mayo Clinic

Blood Advances | August 2, 2023 | Volume: 7 | Issue: 20 | Pages: 6266-6274

10.1182/bloodadvances.2023010334 | PMID 37530622 Get It

Abstract Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). Patients with R/R cHL who were brentuximab vedotin (BV)–naive (cohort A), received BV after auto-HCT (cohort B), or received BV before and/or after auto-HCT (cohort C) were administered with nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. Patients in cohort C with complete remission (CR) for 1 year could discontinue nivolumab and resume upon relapse. Among 243 patients (cohort A, n = 63; B, n = 80; and C, n = 100), the objective response rate (ORR) was 71.2% (95% confidence interval [CI], 65.1-76.8); the CR rate was 21.4% (95% CI, 16.4-27.1). Median duration of response, CR, and partial remission were 18.2 (95% CI, 14.7-26.1), 30.3, and 13.5 months, respectively. Median progression-free survival was 15.1 months (95% CI, 11.3-18.5). Median overall survival (OS) was not reached; OS at 5 years was 71.4% (95% CI, 64.8-77.1). In cohort C, all 3 patients who discontinued in CR and were subsequently re-treated achieved objective response. No new or unexpected safety signals were identified. This 5-year follow-up of CheckMate 205 demonstrated favorable OS and confirmed efficacy and safety of nivolumab in R/R cHL after auto-HCT failure. Results suggest patients may discontinue treatment after persistent CR and reinitiate upon progression. This trial was registered at www.clinicaltrials.gov as #NCT02181713.
How to Recognize and Correct Artifacts on Contrast-Enhanced Mammography
Harper, Laura K , Faulk, Ellen A, Patel, Bhavika , Collins, Patricia, Rochman, Carrie M., Patel, Bhavika K

Mayo Clinic

Journal of Breast Imaging | July 28, 2023 | Volume: 5 | Issue: 4 | Pages: 486-497

10.1093/jbi/wbad041 | PMID 38416909 Get It

Abstract Contrast-enhanced mammography (CEM) has emerged as an important new technology in breast imaging. It can demonstrate a number of imaging artifacts that have the potential to limit interpretation by either obscuring or potentially mimicking disease. Commonly encountered artifacts on CEM include patient motion artifacts (ripple and misregistration), pectoral highlighting artifact, breast implant artifact, halo artifact, corrugation artifact, cloudy fat artifact, contrast artifacts (retention and contamination), skin artifacts (skin line enhancement and skin overexposure), and skin lesions. Skin lesions may demonstrate a variety of imaging appearances and have both benign and malignant etiologies. It is important that the technologist, radiologist, and physicist be aware of potential artifacts and skin enhancement on CEM that may affect interpretation and understand their causes and potential solutions.
Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic
Dunn, Samantha A., Li, Jian , Coles, Charlotte E. , Yamauchi, Chikako , Chang, Jee Suk , Cheng, Skye Hung‐Chun , Meattini, Icro , Ramiah, Duvern , Hijal, Tarek , Poortmans, Philip , Isern, J. , Zissiadis, Yvonne , Offersen, Birgitte Vrou , Hijazi, Hussam, Dengina, Natalia , Belkacémi, Yazid , Luo, Feng, Griffin, Colleen, Collins, Maya, Larios, Dalia, Punglia, Rinaa S. , Wong, Julia S., Spiegel, Daphna Y. , Bellon, Jennifer R. , Ho, Alice Y. , Oladeru, Oluwadamilola T , Yamauchi, Chikako , Chang, Jee Suk , Cheng, Skye Hung-Chun , Kaidar-Person, Orit , Meattini, Icro , Kirby, Anna , Hijal, Tarek , Marta, Gustavo Nader , Isern-Verdum, Josep , Offersen, Birgitte Vrou , Elsayad, Khaled , Lu, Shun , Punglia, Rinaa S , Spiegel, Daphna Y , Jagsi, Reshma , Taghian, Alphonse , Bellon, Jennifer R , Ho, Alice Y , Oladeru, Oluwadamilola T. , Refaat, Tamer , Ryan, Phoebe K. , Warren, Laura Elizabeth , Jagsi, Reshma

Mayo Clinic

JCO Global Oncology | July 20, 2023 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/go.23.00010 | PMID 37471670 Get It

PURPOSE The COVID-19 pandemic has profoundly affected cancer care worldwide, including radiation therapy (RT) for breast cancer (BC), because of risk-based resource allocation. We report the evolution of international breast RT practices during the beginning of the pandemic, focusing on differences in treatment recommendations between countries. MATERIALS AND METHODS Between July and November 2020, a 58-question survey was distributed to radiation oncologists (ROs) through international professional societies. Changes in RT decision making during the first surge of the pandemic were evaluated across six hypothetical scenarios, including the management of ductal carcinoma in situ (DCIS), early-stage, locally advanced, and metastatic BC. The significance of changes in responses before and during the pandemic was examined using chi-square and McNemar-Bowker tests. RESULTS One thousand one hundred three ROs from 54 countries completed the survey. Incomplete responses (254) were excluded from the analysis. Most respondents were from the United States (285), Japan (117), Italy (63), Canada (58), and Brazil (56). Twenty-one percent (230) of respondents reported treating at least one patient with BC who was COVID-19–positive. Approximately 60% of respondents reported no change in treatment recommendation during the pandemic, except for patients with metastatic disease, for which 57.7% (636/1,103; P < .0005) changed their palliative practice. Among respondents who noted a change in their recommendation during the first surge of the pandemic, omitting, delaying, and adopting short-course RT were the most frequent changes, with most transitioning to moderate hypofractionation for DCIS and early-stage BC. CONCLUSION Early in the COVID-19 pandemic, significant changes in global RT practice patterns for BC were introduced. The impact of published results from the FAST FORWARD trial supporting ultrahypofractionation likely confounded the interpretation of the pandemic's independent influence on RT delivery.
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab
Lipsyc-Sharf, Marla , Collins, Laura C. , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Borges, Virginia F. , Krop, Ian E. , Kim, Dewey, Weiß, Jakob, Wagle, Nikhil , Waks, Adrienne G. , Rosenberg, Shoshana , Ruddy, Kathryn J , Schapira, Lidia , Come, Steven , Peppercorn, Jeffrey M , Borges, Virginia F , Krop, Ian E , Weiss, Jakob , Zanudo, Jorge Gomez Tejeda , Partridge, Ann H , Wagle, Nikhil , Waks, Adrienne G , Jain, Esha , Tamimi, Rulla M. , Warner, Ellen , Snow, Craig , Partridge, Ann H.

Mayo Clinic

JCO Precision Oncology | June 26, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.23.00076 | PMID 37364233 Get It

PURPOSE Erb-B2 receptor tyrosine kinase 2 ( ERBB2)–positive breast cancer (BC) is particularly common in young women. Genomic features of ERBB2-positive tumors before and after chemotherapy and trastuzumab (chemo + H) have not been described in young women and are important for guiding study of therapeutic resistance in this population. METHODS From a large prospective cohort of women age 40 years or younger with BC, we identified patients with ERBB2-positive BC and tumor tissue available before and after chemo + H. Whole-exome sequencing (WES) was performed on each tumor and on germline DNA from blood. Tumor-normal pairs were analyzed for mutations and copy number (CN) changes. RESULTS Twenty-two women had successful WES on samples from at least one time point; 12 of these had paired sequencing results from before and after chemo + H and 10 had successful sequencing from either time point. TP53 was the only significantly recurrently mutated gene in both pre- and post-treatment samples. MYC gene amplification was observed in four post-treatment tumors. Seven of 12 patients with paired samples showed acquired and/or clonally enriched alterations in cancer-related genes. One patient had an increased clonality putative activating mutation in ERBB2. Another patient acquired a clonal hotspot mutation in TP53. Other genomic changes acquired in post-treatment specimens included alterations in NOTCH2, STIL, PIK3CA, and GATA3. There was no significant change in median ERBB2 CN (20.3 v 22.6; Wilcoxon P = .79) between paired samples. CONCLUSION ERBB2-positive BCs in young women displayed substantial genomic evolution after treatment with chemo + H. Approximately half of patients with paired samples demonstrated acquired and/or clonally enriched genomic changes in cancer genes. ERBB2 CN changes were uncommon. We identified several genes warranting exploration as potential mechanisms of resistance to therapy in this population.
Longitudinal and experimental investigations of implicit happiness and explicit fear of happiness
Collins, Amanda C , Jordan, D. Gage , Bartoszek, Gregory , Kilgore, Jenna , Lass, Alisson N. S. , Winer, E. Samuel

Mayo Clinic

Cognition and Emotion | June 26, 2023 | Volume: 37 | Issue: 5 | Pages: 973-989

10.1080/02699931.2023.2223907 | PMID 37357839 Get It

Novel whole blood transcriptome signatures of changes in maximal aerobic capacity in response to endurance exercise training in healthy women
LaRocca, Thomas J. , Smith, M. , Freeberg, Kaitlin A. , Craighead, Daniel H. , Helmuth, Timothy , Robinson, Matthew M. , Bryan, Angela D. , Seals, Douglas R. , Smith, Meghan E , Bryan, Angela D , Seals, Douglas R , Robinson, Matthew M , Nair, K. Sreekumaran

Mayo Clinic

Physiological Genomics | June 19, 2023 | Volume: 55 | Issue: 8 | Pages: 338-344

10.1152/physiolgenomics.00017.2023 | PMID 37335021 Get It

Maximal aerobic exercise capacity [maximal oxygen consumption (V̇o 2max )] is one of the strongest predictors of morbidity and mortality. Aerobic exercise training can increase V̇o 2max , but inter-individual variability is marked and unexplained physiologically. The mechanisms underlying this variability have major clinical implications for extending human healthspan. Here, we report a novel transcriptome signature related to ΔV̇o 2max with exercise training detected in whole blood RNA. We used RNA-Seq to characterize transcriptomic signatures of ΔV̇o 2max in healthy women who completed a 16-wk randomized controlled trial comparing supervised, higher versus lower aerobic exercise training volume and intensity (4 training groups, fully crossed). We found significant baseline gene expression differences in subjects who responded to aerobic exercise training with robust versus little/no ΔV̇o 2max , and differentially expressed genes/transcripts were mostly related to inflammatory signaling and mitochondrial function/protein translation. Baseline gene expression signatures associated with robust versus little/no ΔV̇o 2max were also modulated by exercise training in a dose-dependent manner, and they predicted ΔV̇o 2max in this and a separate dataset. Collectively, our data demonstrate the potential utility of using whole blood transcriptomics to study the biology of inter-individual variability in responsiveness to the same exercise training stimulus.
THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW
Binkley, Michael S., Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Steiner, Raphaël , Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, Xieyi , Advani, Ranjana H. , Metzger, Monika L. , Wirth, A., Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, Andrea K. , Koenig, Julie L. , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Kendi, J. Al, Rahbi, Nasser Al, Balogh, Alex, Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Chang, Ilsung , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Сенченко, М. А. , Reeves, Mark E. , Terezakis, Stephanie , Fergusson, Pamela, Kelly, Kara M. , Advani, Ranjana H , Hopkins, David , Senchenko, Maria Anatolevna , Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Hodgson, David C. , Akhtar, Saad , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Kendi, J. Al, Levis, Mario , Ricardi, Umberto , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Volchkov, Egor Vasilevich , Reeves, M., Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Fergusson, P., Northend, Michael , Shankar, Ananth , Maurer, Matthew J. , Natkunam, Yasodha , Eichenauer, Dennis A. , Hoppe, Richard T.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 100-101

10.1002/hon.3163_62 Get It

Inflammatory Arthritis After COVID-19: A Case Series
Yadav, Siddhant, Bonnes, Sara L. , Gilman, Elizabeth A. , Mueller, Michael , Collins, Nerissa M. , Mueller, Michael R , Hurt, Ryan T. , Ganesh, Ravindra , Mueller, Michael R., Ganesh, Ravindra

Mayo Clinic

American Journal of Case Reports | June 6, 2023 | Volume: 24 | Issue: No issue available | Pages: No page available

10.12659/ajcr.939870 | PMID 37368875 Get It